{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:50:16Z","timestamp":1787986216248,"version":"build-2784847793"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1","funder":[{"DOI":"10.13039\/100004417","name":"The Global Fund to Fight AIDS, Tuberculosis and Malaria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1093\/jac\/dkw358","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T00:39:03Z","timestamp":1474591143000},"page":"210-219","source":"Crossref","is-referenced-by-count":48,"title":["HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa"],"prefix":"10.1093","volume":"72","author":[{"given":"K.","family":"Steegen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bronze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Papathanasopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"van Zyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Goedhals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Variava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"MacLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. S.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"key":"2016121607301286000_72.1.210.1","unstructured":"UNAIDS. AIDS by the Numbers . http:\/\/www.unaids.org\/en\/resources\/documents\/2015\/AIDS_by_the_numbers_2015 ."},{"key":"2016121607301286000_72.1.210.2","unstructured":"UNAIDS. UNAIDS announces that the goal of 15 million people on life-saving HIV treatment by 2015 has been met nine months ahead of schedule . http:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2015\/july\/20150714_PR_MDG6report ."},{"key":"2016121607301286000_72.1.210.3","unstructured":"South African Antiretroviral Treatment Guidelines . http:\/\/www.hst.org.za\/sites\/default\/files\/sa_ART_Guidelines1.pdf ."},{"key":"2016121607301286000_72.1.210.4","unstructured":"The South African Antiretroviral Treatment Guidelines . http:\/\/www.sahivsoc.org\/Files\/Clinical_Guidelines_for_the_Management_of_HIV_AIDS_in_Adults_Adolescents_2010.pdf ."},{"key":"2016121607301286000_72.1.210.5","unstructured":"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents . http:\/\/www.sahivsoc.org\/Files\/2013%20ART%20Treatment%20Guidelines%20Final%2025%20March%202013%20corrected.pdf ."},{"key":"2016121607301286000_72.1.210.6","unstructured":"National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents and Adults . http:\/\/www.sahivsoc.org\/Files\/Consolidated%20ART%20guidelines%20_Jan%202015.pdf ."},{"issue":"Suppl 2","key":"2016121607301286000_72.1.210.7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350801302S04","article-title":"Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment","volume":"13","author":"Bennett","year":"2008","journal-title":"Antivir Ther"},{"key":"2016121607301286000_72.1.210.8","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328313bf87"},{"key":"2016121607301286000_72.1.210.9","doi-asserted-by":"crossref","first-page":"pii=1000117","DOI":"10.4172\/2155-6113.1000117","article-title":"Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa","volume":"2","author":"El-Khatib","year":"2011","journal-title":"J AIDS Clin Res"},{"key":"2016121607301286000_72.1.210.10","doi-asserted-by":"publisher","DOI":"10.1086\/648444"},{"key":"2016121607301286000_72.1.210.11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/135965350901400414","article-title":"HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme","volume":"14","author":"Orrell","year":"2009","journal-title":"Antivir Ther"},{"key":"2016121607301286000_72.1.210.12","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181bc478b"},{"key":"2016121607301286000_72.1.210.13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3851\/IMP1985","article-title":"Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy","volume":"17","author":"Wallis","year":"2012","journal-title":"Antivir Ther"},{"key":"2016121607301286000_72.1.210.14","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182278c29"},{"key":"2016121607301286000_72.1.210.15","doi-asserted-by":"publisher","DOI":"10.1086\/587109"},{"key":"2016121607301286000_72.1.210.16","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2011.0136"},{"key":"2016121607301286000_72.1.210.17","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318228667f"},{"key":"2016121607301286000_72.1.210.18","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.22189"},{"key":"2016121607301286000_72.1.210.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072152"},{"key":"2016121607301286000_72.1.210.20","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2652"},{"key":"2016121607301286000_72.1.210.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118145"},{"key":"2016121607301286000_72.1.210.22","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328356886d"},{"key":"2016121607301286000_72.1.210.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067188"},{"issue":"Suppl 2","key":"2016121607301286000_72.1.210.24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/135965350801302S09","article-title":"Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004","volume":"13","author":"Pillay","year":"2008","journal-title":"Antivir Ther"},{"key":"2016121607301286000_72.1.210.25","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833a097b"},{"key":"2016121607301286000_72.1.210.26","unstructured":"Bronze M , Moodley K , Steegen K et al . Development and validation of a one-step genotyping protocol encompassing HIV-1 protease and reverse transcriptase for patient antiretroviral drug resistance monitoring. First International Conference of the African Society for Laboratory Medicine, Cape Town, South Africa."},{"key":"2016121607301286000_72.1.210.27","unstructured":"Claassen M , Van Zyl GU . The improvement, validation and quality assurance of in-house HIV-1 antiretroviral resistance tests for practical use in resistance monitoring of patients receiving antiretroviral combination therapy at Tygerberg Hospital Family Clinic. http:\/\/scholar.sun.ac.za\/handle\/10019.1\/42809 ."},{"key":"2016121607301286000_72.1.210.28","unstructured":"Lukhwareni A , Bronze M , Ledwaba J et al . Validation of a robust in-house genotyping assay for the detection of HIV-1 antiretroviral drug resistance. Pathpoint Conference, Cape Town, South Africa."},{"key":"2016121607301286000_72.1.210.29","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh340"},{"key":"2016121607301286000_72.1.210.30","doi-asserted-by":"publisher","DOI":"10.1080\/10635150390235520"},{"key":"2016121607301286000_72.1.210.31","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msp077"},{"key":"2016121607301286000_72.1.210.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009490"},{"key":"2016121607301286000_72.1.210.33","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200212153-00006"},{"key":"2016121607301286000_72.1.210.34","first-page":"31","article-title":"Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients","volume":"27","author":"Turner","year":"2004","journal-title":"New Microbiol"},{"key":"2016121607301286000_72.1.210.35","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2.1.147"},{"key":"2016121607301286000_72.1.210.36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3437-3446.2002"},{"key":"2016121607301286000_72.1.210.37","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000232228.88511.0b"},{"key":"2016121607301286000_72.1.210.38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020208"},{"key":"2016121607301286000_72.1.210.39","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit114"},{"key":"2016121607301286000_72.1.210.40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01668-12"},{"key":"2016121607301286000_72.1.210.41","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.3.1395-1400.2005"},{"key":"2016121607301286000_72.1.210.42","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001280-00012"},{"key":"2016121607301286000_72.1.210.43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1413-1415.2004"},{"key":"2016121607301286000_72.1.210.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311274"},{"key":"2016121607301286000_72.1.210.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61164-2"},{"key":"2016121607301286000_72.1.210.46","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis261"},{"key":"2016121607301286000_72.1.210.47","unstructured":"Paton NI , Kityo C , Thompson J et al . Impact of NRTI cross-resistance on second-line PI+NRTI therapy outcomes in Africa. In: Abstracts of the Twenty-second Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2015. Abstract 119. Foundation for Retrovirology and Human Health, Alexandria, VA, USA."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/1\/210\/8497071\/dkw358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T01:36:45Z","timestamp":1657330605000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1093\/jac\/dkw358"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw358","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,22]]}}}